Table 4.
Incidence of Secondary End Points and Other Outcomes.*
| Outcome | Trandolapril (N=4158) | Placebo (N=4132) | Hazard Ratio (95% CI) | P Value |
|---|---|---|---|---|
| no. of patients (%) | ||||
| Planned analyses | ||||
| Death from cardiovascular causes, nonfatal MI, revascularization, or unstable angina | 1060 (25.5) | 1068 (25.8) | 0.98 (0.90–1.07) | 0.64 |
| Death from cardiovascular causes, nonfatal MI, revascularization, unstable angina, or new CHF | 1091 (26.2) | 1122 (27.1) | 0.96 (0.88–1.04) | 0.30 |
| Death from cardiovascular causes, nonfatal MI, revascularization, unstable angina, new CHF requiring hospitalization, or stroke | 1125 (27.1) | 1164 (28.2) | 0.95 (0.88–1.03) | 0.23 |
| Death from cardiovascular causes, nonfatal MI, revascularization, unstable angina, new CHF requiring hospitalization, stroke, or peripheral vascular disease requiring intervention, angioplasty, bypass surgery, or aneurysm repair | 1205 (29.0) | 1243 (30.1) | 0.95 (0.88–1.03) | 0.23 |
| Death from cardiovascular causes, nonfatal MI, revascularization, unstable angina, new CHF, stroke, peripheral vascular disease, or cardiac arrhythmia requiring hospitalization | 1284 (30.9) | 1311 (31.7) | 0.96 (0.89–1.04) | 0.35 |
| Death from cardiovascular causes or nonfatal MI (original outcome in PEACE Trial) | 344 (8.3) | 352 (8.5) | 0.97 (0.83–1.12) | 0.67 |
| Post hoc analyses | ||||
| Death from cardiovascular causes, nonfatal MI, or stroke (outcome in HOPE) | 396 (9.5) | 420 (10.2) | 0.93 (0.81–1.07) | 0.32 |
| Death from cardiovascular causes, nonfatal MI, or cardiac arrest (outcome in EUROPA) | 346 (8.3) | 356 (8.6) | 0.96 (0.83–1.12) | 0.62 |
| CHF | ||||
| As primary cause of hospitalization or death | 115 (2.8) | 152 (3.7) | 0.75 (0.59–0.95) | 0.02 |
| As primary cause of hospitalization | 105 (2.5) | 134 (3.2) | 0.77 (0.60–1.00) | 0.05 |
| As primary cause of death | 15 (0.4) | 25 (0.6) | 0.59 (0.31–1.13) | 0.11 |
| Stroke | 71 (1.7) | 92 (2.2) | 0.76 (0.56–1.04) | 0.09 |
| Onset of new diabetes† | 335 (9.8) | 399 (11.5) | 0.83 (0.72–0.96) | 0.01 |
*
CI denotes confidence interval, MI myocardial infarction, CHF congestive heart failure, PEACE the Prevention of Events with Angiotensin Converting Enzyme Inhibition Trial, HOPE the Heart Outcomes Prevention Evaluation,15 and EUROPA the European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease.16
†
The analysis included 3432 patients in the trandolapril group and 3472 patients in the placebo group and excluded patients with diabetes at baseline.